Ironsides Asset Advisors’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Ironsides Asset Advisors’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-7,964	Closed	-$368K	–	164
2014 Q3	$368K	Hold	7,964	–	–	0.11%	123
2014 Q2	$348K	Buy	+7,964	New	+$323K	0.1%	128

Other funds holding PBE

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

TAM

Trillium Asset Management Boston, Massachusetts $3.01B AUM 19.96% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

SAM

SignalPoint Asset Management Springfield, Missouri $411M AUM 23.81% 1-Year Est. Return

HBT

Hills Bank & Trust North Liberty, Iowa $2.07B AUM 13.46% 1-Year Est. Return

Ironsides Asset Advisors's PBE Position: Q4 2014 in Review

Ironsides Asset Advisors sold out of Invesco Biotechnology & Genome ETF (PBE) in Q4 2014, closing a stake of 7,964 shares — an estimated $368K sold.

Ironsides Asset Advisors first reported a position in PBE in Q2 2014 and held it in 2 quarters. The position peaked at $368K in Q3 2014. 82 funds tracked by Wall St. Rank hold PBE as of Q4 2014.

Ironsides Asset Advisors reported no remaining Invesco Biotechnology & Genome ETF position as of Q4 2014 after selling out during the quarter.
Ironsides Asset Advisors sold 7,964 Invesco Biotechnology & Genome ETF shares in Q4 2014, an estimated $368K.
Ironsides Asset Advisors first reported a position in Invesco Biotechnology & Genome ETF in Q2 2014 and held it in 2 quarters.
Ironsides Asset Advisors's Invesco Biotechnology & Genome ETF position peaked at $368K in Q3 2014.
82 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q4 2014.

Based on Ironsides Asset Advisors's 13F filing for Q4 2014, filed 11 Feb 2015.